Drug
Cr845 KG
Cr845 KG: highest development phase Phase 3, developed by Cara Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Cara Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CR845 0.5 mcg/kg NCT03998163 | Phase 3 | Uremic Pruritus |
| CR845 0.5 mcg/kg NCT03422653 | Phase 3 | Uremic Pruritus |
| CR845 0.5 mcg/kg NCT03636269 | Phase 3 | Uremic Pruritus |
| CR845 IV 1 mcg/kg NCT02542384 | Phase 2/3 | Post Abdominal Surgery Pain |
| CR845 0.5 mcg/kg NCT02858726 | Phase 2/3 | Uremic Pruritus |
| CR845 0.5 mcg/kg IV NCT04019574 | Phase 1 | Healthy |
| CR845 0.5 mcg/kg NCT05533008 | Phase 1 | Hemodialysis |
Latest
No recent events.
Follow Cr845 KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.